Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions
Authors
Keywords
-
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-12-13
DOI
10.1007/s00280-022-04494-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies
- (2022) Yingxin Zhao et al. Drug Design Development and Therapy
- New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
- (2022) Annalisa Marcuzzi et al. Pharmaceuticals
- Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
- (2021) Camille Keenan et al. Frontiers in Immunology
- Pediatric Hemophagocytic Lymphohistiocytosis (HLH)
- (2020) Scott Canna et al. BLOOD
- Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy
- (2020) Georgia Griffin et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- Ruxolitinib for the treatment of graft-versus-host disease
- (2020) Haris Ali et al. Expert Review of Clinical Immunology
- Outcome analysis of pediatric hemophagocytic lymphohistiocytosis
- (2020) Tsung-Yen Chen et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis
- (2020) Li Jianguo et al. PEDIATRICS
- Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy
- (2020) Adam S. Darwich et al. Annual Review of Pharmacology and Toxicology
- Mechanisms of Action of Ruxolitinib in Murine Models of Hemophagocytic Lymphohistiocytosis
- (2019) Sabrin Albeituni et al. BLOOD
- Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects
- (2019) Vassilios Aslanis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO)
- (2019) Michael B. Jordan et al. PEDIATRIC BLOOD & CANCER
- Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis
- (2019) Jingshi Wang et al. HAEMATOLOGICA
- Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial
- (2019) Asra Ahmed et al. Lancet Haematology
- FDA Approval Summary: Ruxolitinib for Treatment of Steroid‐Refractory Acute Graft‐Versus‐Host Disease
- (2019) Donna Przepiorka et al. ONCOLOGIST
- Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
- (2019) Elena Maria Elli et al. Frontiers in Oncology
- Misconceptions and issues regarding allometric scaling during the drug development process
- (2018) Iftekhar Mahmood Expert Opinion on Drug Metabolism & Toxicology
- Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy
- (2018) Joshua C. Euteneuer et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Hemophagocytic Lymphohistiocytosis: Clinical Presentations and Diagnosis
- (2018) Kimberly A. Risma et al. Journal of Allergy and Clinical Immunology-In Practice
- Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis
- (2016) R. Das et al. BLOOD
- Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice
- (2016) Sophia Maschalidi et al. BLOOD
- Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review
- (2016) Anna Hayden et al. BLOOD REVIEWS
- Allometry Is a Reasonable Choice in Pediatric Drug Development
- (2016) Tao Liu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management
- (2016) Akira Morimoto et al. PEDIATRICS INTERNATIONAL
- Hemophagocytic Lymphohistiocytosis in Children: Pathogenesis and Treatment
- (2016) Eiichi Ishii Frontiers in Pediatrics
- A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
- (2015) Mignon L. Loh et al. PEDIATRIC BLOOD & CANCER
- A Population Pharmacokinetic Model of Valproic Acid in Pediatric Patients with Epilepsy: A Non-Linear Pharmacokinetic Model Based on Protein-Binding Saturation
- (2014) Junjie Ding et al. CLINICAL PHARMACOKINETICS
- Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects
- (2013) Hagop M. Kantarjian et al. Clinical Lymphoma Myeloma & Leukemia
- Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF)
- (2013) Xuejun Chen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A Pharmacokinetic Standard for Babies and Adults
- (2013) Nick Holford et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- A Bodyweight-Dependent Allometric Exponent for Scaling Clearance Across the Human Life-Span
- (2012) Chenguang Wang et al. PHARMACEUTICAL RESEARCH
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
- (2011) Martin Bergstrand et al. AAPS Journal
- The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model?
- (2010) Iftekhar Mahmood BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans
- (2010) A. D. Shilling et al. DRUG METABOLISM AND DISPOSITION
- To scale or not to scale: the principles of dose extrapolation
- (2009) Vijay Sharma et al. BRITISH JOURNAL OF PHARMACOLOGY
- Meropenem Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation in the Neonate
- (2008) John S. Bradley et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started